| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
7-Methylcoumarin targets cytochrome P450 2A6 (CYP2A6), a key enzyme in the metabolism of nicotine, coumarin, and various drugs. By inhibiting CYP2A6, the compound can modulate the metabolism of substrates processed by this enzyme. It is also reported to have hepatoprotective activity, likely mediated through its antioxidant properties, which help protect liver cells from oxidative damage. The compound may also interact with other CYP450 isoforms, though its primary reported target is CYP2A6. Its antioxidant effects contribute to its protective activities in cellular models.
|
|---|---|
| ln Vitro |
In vitro, 7-Methylcoumarin inhibits CYP2A6 activity, as demonstrated in enzyme assays using recombinant CYP2A6 or human liver microsomes. It shows hepatoprotective activity in cell-based models of liver injury, likely due to its potent antioxidant effects that reduce oxidative stress and cell death. The compound may also exhibit anti-inflammatory activities in various cell types. However, detailed IC50 values for CYP2A6 inhibition and specific cellular assay data are not extensively reported in the available literature. The compound is primarily used as a research tool for studying CYP2A6-mediated metabolism.
|
| ln Vivo |
In vivo, 7-Methylcoumarin has shown ameliorative effects in animal models, as reported for 7-methylcoumarin and related compounds. Its hepatoprotective activity is expected to be mediated through antioxidant mechanisms that reduce oxidative damage in the liver. The compound may also modulate drug metabolism by inhibiting CYP2A6 in vivo, affecting the pharmacokinetics of co-administered drugs that are substrates of this enzyme. However, specific in vivo efficacy data for this compound are not extensively detailed in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 7-Methylcoumarin typically involve CYP2A6 inhibition assays using human liver microsomes or recombinant CYP2A6 enzyme. The assay is performed in 100 mM potassium phosphate buffer (pH 7.4) containing an NADPH-regenerating system. The compound is incubated with the enzyme and a fluorogenic substrate (e.g., coumarin or 7-hydroxycoumarin) at 37°C for 30 minutes. Product formation is measured fluorometrically (excitation 390 nm, emission 440 nm). The IC50 for CYP2A6 inhibition is determined from dose-response curves (typically 0.01-100 μM).
|
| Cell Assay |
In vitro cellular assays for 7-Methylcoumarin typically use primary hepatocytes or hepatic cell lines such as HepG2 or AML12 cells to assess hepatoprotective activity. Cells are cultured in DMEM with 10% FBS and pre-treated with various concentrations of the compound (typically 1-100 μM) for 2-4 hours, followed by exposure to an oxidative stress inducer (e.g., H2O2, CCl4, or acetaminophen) for 6-24 hours. Cell viability is assessed using MTT or LDH release assays. Antioxidant activity is measured by intracellular ROS levels using DCFH-DA staining. Inflammatory markers (TNF-α, IL-6) can be measured by ELISA.
|
| Animal Protocol |
In vivo animal studies with 7-Methylcoumarin typically use rodent models of liver injury. Mice or rats are administered the compound orally or intraperitoneally at doses of 10-100 mg/kg for 3-7 days prior to induction of liver injury with CCl4 or acetaminophen. Liver function is assessed by measuring serum ALT, AST, and bilirubin levels. Hepatic oxidative stress markers (MDA, GSH, SOD) are measured in liver homogenates. Histopathological examination of liver sections (H&E staining) is performed to assess tissue damage. CYP2A6 activity in vivo can be assessed using probe substrates such as coumarin.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-Methylcoumarin: The compound is a small lipophilic molecule with a molecular weight of 160.17. It is expected to be well absorbed orally and distributed throughout the body. The compound is metabolized primarily by CYP450 enzymes, including CYP2A6, to hydroxylated metabolites that are conjugated and excreted in urine. The elimination half-life is likely short (a few hours) due to rapid metabolism. Specific PK parameters such as Cmax, AUC, and bioavailability are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 7-Methylcoumarin is not extensively reported in the available literature. As a coumarin derivative, it may have potential hepatotoxic effects at high doses, though 7-methylcoumarin itself has been reported to have hepatoprotective activity at lower doses. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include assessment of cytotoxicity in hepatic cell lines and acute oral toxicity in rodents. No specific genotoxicity or carcinogenicity data are reported.
|
| References | |
| Additional Infomation |
7-Methylcoumarin is a member of the coumarin family.
7-Methylcoumarin (CAS 2445-83-2) is a methylated coumarin derivative that serves as a selective inhibitor of CYP2A6. It is a white to light yellow crystalline powder with a melting point of 127-130°C. The compound has been studied for its hepatoprotective properties, attributed to its potent antioxidant effects that protect against oxidative stress-induced liver injury. It is used as a research tool in drug metabolism studies to investigate CYP2A6-mediated pathways and as a potential therapeutic agent for liver protection. The compound is not approved for clinical use and is available for research purposes only. |
| Molecular Formula |
C10H8O2
|
|---|---|
| Molecular Weight |
160.1693
|
| Exact Mass |
160.052
|
| CAS # |
2445-83-2
|
| PubChem CID |
17131
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
313.1±0.0 °C at 760 mmHg
|
| Melting Point |
128-130 °C(lit.)
|
| Flash Point |
125.9±19.5 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
1.85
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
220
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DLHXRDUXNVEIEY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8O2/c1-7-2-3-8-4-5-10(11)12-9(8)6-7/h2-6H,1H3
|
| Chemical Name |
7-methylchromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~624.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2434 mL | 31.2168 mL | 62.4337 mL | |
| 5 mM | 1.2487 mL | 6.2434 mL | 12.4867 mL | |
| 10 mM | 0.6243 mL | 3.1217 mL | 6.2434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
